5-7 December 2017

London, UK

Register here

Day One
Wednesday, 6th December 2017

Day Two
Thursday, 7th December 2017

08.30
Registration

09.00
Chair’s Opening Remarks

09.10
Isolation of Tumour Cells and Tumour-Infiltrating Immune Cell Subpopulations for Optimised Downstream Analysis

Synopsis

  • Optimised and automated dissociation of tumour tissue resulting in high yield, viability and improved cell surface marker preservation
  • Methods for the untouched isolation of tumour cells from mouse, human, and xenotransplanted tumour tissue
  • A novel workflow allowing for the automated isolation and analysis of TILs, promoting immunotherapy research

Succeed in Closely Mimicking the Human Tumour Microenvironment in Preclinical Models

09.40
Discovering Resistance Mechanisms by Insertional Mutagenesis in Mice

Synopsis

Session 11 till 12

10.10
A Slice of Reality: Using Tumour Slices to Study the Tumour Microenvironment

Synopsis

Session 11 till 12

10.40
Revealing the Molecular Determinants of Therapeutic Response With 3D BiologyTM Technology

  • Doug Hinerfeld Principal Product Application Scientist , NanoString Technologies

Synopsis

  • NanoString 3D Biology Technology enables simultaneous, multi-analyte analysis for integrated DNA, RNA, and Protein insight from 2 FFPE sections or minimal frozen tumor specimens.
  • Given the resource intensiveness of PDX preclinical studies, attaining maximal information from minimum sample about therapeutic response and resistance is critical.
  • Using 3D Biology Technology, we have uncovered molecular mechanisms of MEKi response in triple negative breast cancer PDX models.

11.10
Targeting the Tumour Microenvironment Signals in a Xenograft Model of Oesophageal Adenocarcinoma

Synopsis

  • Using In vitro cultures of cancer cells fail to integrate the tumour microenvironment signals
  • Utilising BMP inhibition to represent an attractive therapeutic option in oesophageal cancer

Back Translational Analysis for Improved Preclinical Decision Making – Combatting Unsustainable Failure Rates

11.40
Morning Refreshments

12.10
Evaluation of a “PDX Clinical Trial” as Tool for Predicting Efficacy in Combination with Identification of Biomarkers

Synopsis

  • PDX Clinical Trial; NSCLC PDX models; CRC PDX models
  • Comparing different methods to define response; intermediate response, no response
  • Analysing historical data and collection of tissues for biomarker signature analysis

12.40
Sophisticatedly Simple Approaches to Dose Translation

Synopsis

  • Explore dose translation: complex versus simple approaches based on safety and efficacy using xenografts
  • Safety example: Osimertinib
  • Efficacy example: Pembrolizumab
  • Highlighting the pitfalls of complex approaches with regards to cost, speed and accuracy

13.10
Preclinical Models Evaluating the Bispecific Immunomodulatory Antibody ATOR-1015 Targeting OX40 and CTLA

Synopsis

  • In vitro evaluation of bispecific immunomodulatory antibodies targeting a checkpoint inhibitor and an agonist target
  • Opportunities and pitfalls of in vivo models to evaluate bispecific immunomodulatory antibodies- the syngeneic, humanised and transgenic models

Utilising Preclinical Model Design To Better Model Tumour Heterogeneity

13.40
Networking Lunch

14.40
How To Advance PDX Tumour Biology Platforms Towards Enhancing Present Cancer Therapy Approaches?

Synopsis

  • Tumour is a heterogeneous tissue and hence any primary PDX model may not represent a therapeutically competent animal model
  • Establishing metastatic PDX models in parallel to the same patients’ clinical trials for gaining an early predictive power on tumour evolution during development of cancer therapy resistance
  • Exploiting such models in humanised contexts for functional biomarker discovery towards developing precise cancer therapeutics

15.10
Development of BT1718, a Bicycle Drug Conjugate (BDC) For Solid Tumours

  • Gavin Bennett Head of Preclinical Development, Bicycle Therapeutics

Synopsis

  • BT1718 produces rapid regression of target-expressing tumours
  • Bicycle drug conjugates offer rapid and complete penetration into solid tumours
  • Short half-life and renal clearance offer novel opportunity for “short, sharp hit”: efficacy with reduced systemic toxicology

15.40
Chairperson’s Closing Remarks

15.50
Close of the 6th Annual Tumour Models London Summit 2017